205 related articles for article (PubMed ID: 33144562)
1. Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy.
Guan Y; Jiang S; Ye W; Ren X; Wang X; Zhang Y; Yin M; Wang K; Tao Y; Yang J; Cao D; Cheng Y
Cell Death Dis; 2020 Nov; 11(11):948. PubMed ID: 33144562
[TBL] [Abstract][Full Text] [Related]
2. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer.
Tekedereli I; Alpay SN; Tavares CD; Cobanoglu ZE; Kaoud TS; Sahin I; Sood AK; Lopez-Berestein G; Dalby KN; Ozpolat B
PLoS One; 2012; 7(7):e41171. PubMed ID: 22911754
[TBL] [Abstract][Full Text] [Related]
3. Suppression of eEF-2K-mediated autophagy enhances the cytotoxicity of raddeanin A against human breast cancer cells in vitro.
Guan YD; Jiang SL; Yu P; Wen M; Zhang Y; Xiao SS; Xu XJ; Cheng Y
Acta Pharmacol Sin; 2018 Apr; 39(4):642-648. PubMed ID: 29239350
[TBL] [Abstract][Full Text] [Related]
4. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
5. Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.
Bircan HA; Gurbuz N; Pataer A; Caner A; Kahraman N; Bayraktar E; Bayraktar R; Erdogan MA; Kabil N; Ozpolat B
Lung Cancer; 2018 Oct; 124():31-39. PubMed ID: 30268477
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting eEF-2 kinase-mediated autophagy enhanced the cytocidal effect of AKT inhibitor on human nasopharyngeal carcinoma.
Zhao YY; Tian Y; Liu L; Zhan JH; Hou X; Chen X; Zhou T; Huang Y; Zhang L
Drug Des Devel Ther; 2018; 12():2655-2663. PubMed ID: 30214154
[TBL] [Abstract][Full Text] [Related]
7. eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206.
Cheng Y; Ren X; Zhang Y; Patel R; Sharma A; Wu H; Robertson GP; Yan L; Rubin E; Yang JM
Cancer Res; 2011 Apr; 71(7):2654-63. PubMed ID: 21307130
[TBL] [Abstract][Full Text] [Related]
8. Targeting elongation factor-2 kinase (eEF-2K) induces apoptosis in human pancreatic cancer cells.
Ashour AA; Abdel-Aziz AA; Mansour AM; Alpay SN; Huo L; Ozpolat B
Apoptosis; 2014 Jan; 19(1):241-58. PubMed ID: 24193916
[TBL] [Abstract][Full Text] [Related]
9. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
11. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
[TBL] [Abstract][Full Text] [Related]
12. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
13. What is the impact of eukaryotic elongation factor 2 kinase on cancer: A systematic review.
Li S; Li Y; Bai Y
Eur J Pharmacol; 2019 Aug; 857():172470. PubMed ID: 31226250
[TBL] [Abstract][Full Text] [Related]
14. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.
Xu S; Li S; Guo Z; Luo J; Ellis MJ; Ma CX
Mol Cancer Ther; 2013 Aug; 12(8):1665-75. PubMed ID: 23689832
[TBL] [Abstract][Full Text] [Related]
15. Eukaryotic elongation factor-2 kinase regulates the cross-talk between autophagy and pyroptosis in doxorubicin-treated human melanoma cells in vitro.
Yu P; Wang HY; Tian M; Li AX; Chen XS; Wang XL; Zhang Y; Cheng Y
Acta Pharmacol Sin; 2019 Sep; 40(9):1237-1244. PubMed ID: 30914761
[TBL] [Abstract][Full Text] [Related]
16. HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.
Chen SM; Guo CL; Shi JJ; Xu YC; Chen Y; Shen YY; Su Y; Ding J; Meng LH
Int J Cancer; 2014 Nov; 135(10):2462-74. PubMed ID: 24706460
[TBL] [Abstract][Full Text] [Related]
17. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
[TBL] [Abstract][Full Text] [Related]
19. Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion.
Ashour AA; Gurbuz N; Alpay SN; Abdel-Aziz AA; Mansour AM; Huo L; Ozpolat B
J Cell Mol Med; 2014 Nov; 18(11):2235-51. PubMed ID: 25215932
[TBL] [Abstract][Full Text] [Related]
20. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
